[go: up one dir, main page]

WO2008140598A3 - Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci - Google Patents

Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci Download PDF

Info

Publication number
WO2008140598A3
WO2008140598A3 PCT/US2007/086335 US2007086335W WO2008140598A3 WO 2008140598 A3 WO2008140598 A3 WO 2008140598A3 US 2007086335 W US2007086335 W US 2007086335W WO 2008140598 A3 WO2008140598 A3 WO 2008140598A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium strains
mycobacteria
pharmaceutic
methods
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/086335
Other languages
English (en)
Other versions
WO2008140598A2 (fr
Inventor
David M. Hone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bacilligen Inc
Original Assignee
Bacilligen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bacilligen Inc filed Critical Bacilligen Inc
Publication of WO2008140598A2 publication Critical patent/WO2008140598A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008140598A3 publication Critical patent/WO2008140598A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention concerne des souches de Mycobacterium génétiquement modifiées qui sont utiles comme agents immunothérapeutiques anti-cancers. Les souches de Mycobacterium génétiquement modifiées présentent de préférence au moins une modification génétique conduisant à une adhérence tissulaire accrue, qui peut être combinée avec des modifications génétiques qui augmentent l'immunopuissance et conduisent à une production d'adjuvants. L'invention concerne également des compositions et des procédés pour le développement desdites souches de Mycobacterium, et des compositions pharmaceutiques et des procédés pour l'utilisation desdites souches de Mycobacterium comme agents thérapeutiques anti-cancer.
PCT/US2007/086335 2006-12-04 2007-12-04 Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci Ceased WO2008140598A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86845006P 2006-12-04 2006-12-04
US60/868,450 2006-12-04

Publications (2)

Publication Number Publication Date
WO2008140598A2 WO2008140598A2 (fr) 2008-11-20
WO2008140598A3 true WO2008140598A3 (fr) 2016-06-09

Family

ID=40002815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086335 Ceased WO2008140598A2 (fr) 2006-12-04 2007-12-04 Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci

Country Status (1)

Country Link
WO (1) WO2008140598A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
KR101928684B1 (ko) * 2009-01-08 2018-12-12 앨버트 아인슈타인 컬리지 오브 메디신, 인크. 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US12359209B2 (en) 2018-04-17 2025-07-15 The Johns Hopkins Unversity Recombinant therapeutic interventions for cancer
CN112601535A (zh) * 2018-04-17 2021-04-02 约翰霍普金斯大学 用于癌症的重组治疗干预
EP4317441A4 (fr) * 2021-03-22 2025-09-17 Clipsbnc Co Ltd Nouvelle souche recombinée de mycobacterium smegmatis et son utilisation
CN118715022A (zh) * 2022-02-11 2024-09-27 布坦坦研究所 包含重组分枝杆菌菌株的组合物、其用途和用于预防和/或治疗癌症的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220811A1 (en) * 2002-04-05 2005-10-06 Stewart Cole Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
EP1882741A1 (fr) * 2006-07-25 2008-01-30 Institut Pasteur Souche de Mycobacterium exprimant une proteine FAP sous le contrôle d'un promoteur qui est actif en conditions d' hypoxie et ses applications pour la thérapie du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220811A1 (en) * 2002-04-05 2005-10-06 Stewart Cole Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
EP1882741A1 (fr) * 2006-07-25 2008-01-30 Institut Pasteur Souche de Mycobacterium exprimant une proteine FAP sous le contrôle d'un promoteur qui est actif en conditions d' hypoxie et ses applications pour la thérapie du cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LEWIS ET AL.: "Deletion of RD1 from Mycobacterium tuberculosis Mimics Bacille Calmette-Guerin Attenuation.", JOURNAL OF INFECTIOUS DISEASES, vol. 187, no. 1, 2003, pages 117 - 23, XP002987276, DOI: doi:10.1086/345862 *
MIYAMOTO ET AL.: "Aggregation of mycobacteria caused by disruption of fibronectin-attachment protein-encoding gene .", FEMS MICROBIOLOGY LETTERS, vol. 236, no. 2, 2004, pages 227 - 234 *
SECOTT ET AL.: "Fibronectin Attachment Protein Is Necessary for Efficient Attachment and Invasion of Epithelial Cells by Mycobacterium avium subsp. paratuberculosis.", INFECTION AND IMMUNITY, vol. 70, no. 5, May 2002 (2002-05-01), pages 2670 - 2675 *
ZHAO ET AL.: "Characterization of the Fibronectin Binding Motif for a Unique Mycobacterial Fibronectin Attachment Protein, FAP.", J. BIOL CHEM, vol. 274, no. 8, 19 February 1999 (1999-02-19), pages 4521 - 4526 *
ZHAO ET AL.: "ROLE OF A BACILLUS CALMETTE-GUERIN FIBRONECTIN ATTACHMENT PROTEIN IN BCG-INDUCED ANTITUMOR ACTIVITY.", INT. J. CANCER, vol. 86, no. 1, 2000, pages 83 - 88, XP002401487, DOI: doi:10.1002/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R *

Also Published As

Publication number Publication date
WO2008140598A2 (fr) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008140598A3 (fr) Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci
WO2010144344A3 (fr) Peptides spécifiques du récepteur de la mélanocortine
WO2010078457A3 (fr) Procédé de fabrication d&#39;isoprène et d&#39;un co-produit
MX2010004244A (es) Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk).
EP3444352A3 (fr) Production d&#39;un vaccin recombinant dans e. coli par conjugaison enzymatique
EP2698412A3 (fr) Composé contenant un mésogène
WO2006120208A8 (fr) Procedes de preparation de derives de benzylbenzene a substitution glucopyranosyl et intermediaires obtenus selon ces procedes
EP2537857A3 (fr) Formes mutantes de streptolysine O
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
MA35803B1 (fr) Polypeptides d&#39;interleukine-2 mutants
EP4218802A3 (fr) Conjugués pour l&#39;édition de surface cellulaire ciblée
CY1118065T1 (el) Καινοτομες αμινογλυκοσιδες και χρησεις αυτων στη θεραπεια γενετικων διαταραχων
WO2008049758A3 (fr) Colorants pour dispersion, leur fabrication et leur utilisation
ZA200903903B (en) Crystalline solid rasagiline base
WO2011008495A3 (fr) Formulations d&#39;arginase et procédés
WO2007016093A3 (fr) Suppression de peroxyde dans un vecteur d&#39;administration de medicament
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
WO2009042114A3 (fr) Dérivés de phénazine et leurs utilisations
WO2008109142A3 (fr) ARNpi ET UTILISATIONS CORRESPONDANTES
WO2010115751A3 (fr) Dérivés d&#39;oxadiazole
MX2010003200A (es) Composiciones de imatibnib estables.
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2009007535A3 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
WO2010132112A3 (fr) Compositions immunogènes contre la tuberculose
WO2009035959A3 (fr) Methodes de radiofluoration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874337

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874337

Country of ref document: EP

Kind code of ref document: A2